Why the study?
Does preoperative polypharmacy predict postsurgical functional decline in older patients awaiting elective cardiac surgery?
Does preoperative polypharmacy predict postsurgical functional decline in older patients awaiting elective cardiac surgery?
Answers are grounded in this paper and cite their sources.
Preoperative polypharmacy and excessive polypharmacy are independent predictors of functional decline at 1 year in older patients undergoing elective cardiac surgery, offering a potential alternative to complex frailty assessments.
Perioperative medicine is a rapidly expanding multidisciplinary model of care designed to comprehensively assess a wide range of patient domains to minimise the risk of preoperative, intraoperative, and postoperative complications.1 There is increasing evidence that such presurgical assessments are beneficial for risk stratification, particularly in older adults, a highly heterogeneous group that is often characterised by a reduced homeostatic capacity.2, 3 For example, the preoperative identification of frailty, a process that requires adequate staff resources and time given the multidimensional nature of the assessment, has been shown to predict postsurgery delirium, falls, infections, prolonged hospitalization, and mortality.4, 5 However, critical issues arising from these observations are (a) whether anything else can be done in the frail older patient awaiting surgery, apart from selecting the most appropriate anaesthetic protocol, surgical procedure, and rehabilitation plan and (b) whether the presence and the severity of frailty can be identified using alternative, more straightforward, tools. The assessment of polypharmacy, the concomitant use of multiple medicines in a patient, can be helpful in this setting because of the intricate, yet increasingly recognised, associations between polypharmacy, frailty, and adverse outcomes in older patients.6, 7 The latter, notably, can often manifest as functional and/or cognitive decline, with consequent loss of independence, and be erroneously confused with the process of advancing age per se.8 The capacity of preoperative polypharmacy and frailty to predict postsurgical functional decline has been investigated in this issue of the Journal by Arends et al.9 The authors performed a comprehensive assessment of polypharmacy (defined as ≥5 and <10 concomitant medications), excessive polypharmacy (defined as ≥10 concomitant medications), and 11 frailty domains in 518 patients ≥70 years awaiting elective cardiac surgery. The combined prevalence of polypharmacy and excessive polypharmacy was relatively high, 67%. After adjusting for age, sex, and type of surgery, polypharmacy and excessive polypharmacy independently predicted functional decline at 1 year (relative risk, RR, 1.57, 95% CI 1.23 to 1.98 for polypharmacy, and 1.93, 95% CI 1.48 to 2.50 for excessive polypharmacy). When considering individual drug classes according to the Screening Tools of Older Person's Prescriptions (STOPP) and Alert to Right Treatment (START) criteria, the use of cardiovascular drugs, central nervous system (CNS) drugs, and proton pump inhibitors was strongly associated with incident functional decline. The discriminative power (area under the curve, AUC) increased after adding polypharmacy and excessive polypharmacy to a basic model including age, sex, and type of surgery (0.67 vs. 0.62). A similar AUC value was observed after adding measures of frailty instead of polypharmacy (0.67 vs. 0.67). Notably, adding polypharmacy and excessive polypharmacy to the basic model also led to a correct reclassification to a different functional decline risk group in 17% of study participants.9 Pending confirmation in other cohorts, the results of the study by Arends et al. provide some novel insights into the practical applications of assessing polypharmacy in the pre-operative setting. For example, the similar, albeit limited, impact of polypharmacy and frailty in terms of improving the capacity to predict postsurgery functional decline means that the former might theoretically replace the latter in circumstances where a comprehensive geriatric assessment, or other types of frailty assessment, cannot be performed due to limited staff resources or expertise. Furthermore, it is plausible to speculate that deprescribing interventions in the perioperative period might provide beneficial effects on specific functional and cognitive domains, ultimately improving patient outcomes post-surgery. There has been an increasing interest over the last decade in assessing the adverse effects of polypharmacy, particularly inappropriate polypharmacy, and the potential benefits of deprescribing interventions. However, the evidence from published studies remains conflicting in terms of whether polypharmacy independently predicts adverse outcomes and whether deprescribing is effective in reducing such risk or improving quality of life.10, 11 These inconsistencies might be due, at least in part, to between-study differences in patient characteristics, protocol design, duration of follow-up, and degree of inappropriate prescribing at baseline. However, another fundamental issue when investigating polypharmacy is whether the potential risk of adverse outcomes is primarily related to the extent of individual patient exposure to medications, that is, the total number of concomitant drugs, or, instead, driven by specific medications and/or drug classes. Elucidating this point has significant practical implications for the healthcare professionals reviewing a patient's medications. The potential risk of adverse outcomes with specific drug classes has also been extensively investigated over the last 10–15 years. These studies have shown that the long-term use of drugs affecting the CNS, for example, sedatives and anticholinergics, and, albeit with less robust evidence, proton pump inhibitors, is significantly associated with various adverse effects in older adults, including cognitive and functional decline.12-14 Notably, CNS drugs and proton pump inhibitors, in addition to cardiovascular drugs, were also significantly associated with 12-month functional decline in the study by Arends et al.9 This suggests that targeted deprescribing interventions might be particularly beneficial, although it is important to emphasise that, in this study, no assessment of individual medication appropriateness was conducted.9 Even assuming that a targeted deprescribing intervention is scientifically and clinically justified, when should that be implemented? This issue is particularly important in the pre-operative setting. On one hand, it is plausible that specific drugs acting on the CNS might add to the well-known effects of general anaesthesia on a vulnerable brain.15 Such interaction might further increase the risk of cognitive and functional decline after surgery and justify deprescribing interventions as part of routine pre-operative care. On the other hand, the use of specific drugs and drug classes might put patients at higher risk of mid- and long-term functional decline independently of surgery and, consequently, the use of general anaesthetics. This would allow a broader temporal opportunity for medicine evaluation and deprescribing, for example, in a postoperative clinic. In summary, the study by Arends et al. provides some novel insights into the practical utility of polypharmacy as an alternative tool to assess pre-operative frailty and predict postsurgical functional decline.9 At the same time, pending confirmatory studies, it generates several additional questions regarding the nature and the appropriate timing of deprescribing interventions in this and other patient groups. This is particularly important as recent studies have shown that deprescribing specific drugs in older hospitalized patients, for example, antihypertensives and statins, might increase the risk of adverse outcomes following discharge.16 Carefully designed intervention trials that include appropriate comparators and follow-up periods will likely address this important issue and provide additional insights into the efficacy and safety of deprescribing strategies in the older patient population. At the same time, animal and human studies are also required to investigate the possible synergistic adverse effects of general anaesthetics and other agents, for example, benzodiazepines, anticholinergics, and proton pump inhibitors, on CNS homeostasis and recovery capacity. The authors have no conflicts of interest to declare.
No takes yet. Share an insight, caveat, or question.
Mangoni et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: